ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY25 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY25 earnings guidance on Friday morning. The company provided earnings per share guidance of $6.12-6.49 for the period, compared to the consensus earnings per share estimate of $5.56. The company issued revenue guidance of $756-776 million, compared to the consensus revenue estimate of $724.88 million.

Wall Street Analyst Weigh In

A number of research firms recently commented on ANIP. Leerink Partnrs upgraded ANI Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, December 11th. StockNews.com upgraded ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, February 5th. HC Wainwright reaffirmed a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Finally, Leerink Partners assumed coverage on shares of ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $77.71.

ANI Pharmaceuticals Price Performance

ANI Pharmaceuticals stock opened at $54.58 on Friday. The business’s 50-day simple moving average is $57.06 and its 200 day simple moving average is $58.13. The company has a quick ratio of 1.97, a current ratio of 2.74 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.15 billion, a price-to-earnings ratio of -99.24 and a beta of 0.74. ANI Pharmaceuticals has a 12-month low of $52.50 and a 12-month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, February 28th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, topping the consensus estimate of $1.41 by $0.22. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $190.60 million during the quarter, compared to analysts’ expectations of $175.36 million. During the same quarter in the previous year, the company earned $0.04 EPS. ANI Pharmaceuticals’s revenue was up 44.8% on a year-over-year basis. As a group, research analysts anticipate that ANI Pharmaceuticals will post 3.86 earnings per share for the current year.

Insider Buying and Selling

In other news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the transaction, the senior vice president now owns 49,059 shares of the company’s stock, valued at $2,943,540. The trade was a 2.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the sale, the chief financial officer now directly owns 154,468 shares of the company’s stock, valued at approximately $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,300 shares of company stock valued at $584,009 over the last three months. Company insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.